



**HAL**  
open science

# Visible-Light-Enabled Aminocarbonylation of Unactivated Alkyl Iodides with Stoichiometric Carbon Monoxide for Application on Late-Stage Carbon Isotope Labeling

Malvika Sardana, Joakim Bergman, Cecilia Ericsson, Lee Kingston, Magnus Schou, Christophe Dugave, Davide Audisio, Charles Elmore

► **To cite this version:**

Malvika Sardana, Joakim Bergman, Cecilia Ericsson, Lee Kingston, Magnus Schou, et al.. Visible-Light-Enabled Aminocarbonylation of Unactivated Alkyl Iodides with Stoichiometric Carbon Monoxide for Application on Late-Stage Carbon Isotope Labeling. *Journal of Organic Chemistry*, 2019, 84 (24), pp.16076-16085. 10.1021/acs.joc.9b02575 . cea-02488945

**HAL Id: cea-02488945**

**<https://cea.hal.science/cea-02488945v1>**

Submitted on 24 Feb 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## Visible-Light Enabled Aminocarbonylation of Unactivated Alkyl Iodides with Stoichiometric Carbon Monoxide for Application on Late-Stage Carbon Isotope Labeling

Malvika Sardana, Joakim Bergman, Cecilia Ericsson, Lee Peter Kingston, Magnus Schou, Christophe Dugave, Davide Audisio, and Charles S. Elmore

*J. Org. Chem.*, **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.9b02575 • Publication Date (Web): 26 Nov 2019

Downloaded from [pubs.acs.org](https://pubs.acs.org) on December 6, 2019

### Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

**Visible-Light Enabled Aminocarbonylation of Unactivated Alkyl Iodides with Stoichiometric Carbon Monoxide for Application on Late-Stage Carbon Isotope Labeling**

Malvika Sardana\*<sup>1</sup>, Joakim Bergman<sup>2</sup>, Cecilia Ericsson<sup>1</sup>, Lee P Kingston<sup>1</sup>, Magnus Schou<sup>3,4</sup>, Christophe Dugave<sup>5</sup>, Davide Audisio<sup>5</sup>, Charles S Elmore<sup>1</sup>

<sup>1</sup>Early Chemical Development, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden

<sup>2</sup>Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

<sup>3</sup>PET Science Centre at Karolinska Institutet, Precision Medicine, Oncology R&D, AstraZeneca, Stockholm, Sweden

<sup>4</sup>Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden

<sup>5</sup>Service de Chimie Bio-organique et Marquage (SCBM), CEA/DRF/JOLIOT, Université Paris-Saclay, Gif-sur-Yvette, France

\*Email: [Malvika.Sardana@astrazeneca.com](mailto:Malvika.Sardana@astrazeneca.com)

**Abstract**



- |   |                                  |
|---|----------------------------------|
| ✓ Green Solvent                           | ✓ Late-Stage Functionalization   |
| ✓ 1°, 2°, 3° Unactivated and Aryl Iodides | ✓ Compatible with C-14 Chemistry |


1  
2  
3 A visible-light mediated late-stage aminocarbonylation of unactivated alkyl iodides with  
4 stoichiometric amount of carbon monoxide is presented. The method provides a mild, one-step route  
5 to [carbonyl-<sup>13/14</sup>C]alkyl amides; thereby, reducing radioactive waste, and handling of radioactive  
6 material. Easily accessible and low cost equipment and palladium catalyst were successfully used for  
7 the synthesis of a wide range of alkyl amides.  
8  
9  
10  
11  
12  
13

## 14 15 **Introduction**

16  
17  
18 Carbon isotope labeling is a critical tool for the drug discovery and development program. Nearly all  
19 drug molecules contain carbon atoms; thus, no structural modification is required to incorporate a  
20 carbon isotope; moreover, the isotope effect is low for both C-13 and C-14.<sup>1</sup> The stable isotope,  
21 specifically C-13, is commonly used in conjunction with mass spectrometry (MS) for the quantification  
22 of the parent drug in biological samples.<sup>2</sup> Typically, a stable isotope labeled internal standard is  
23 prepared as soon as a single compound is selected and is continuously supplied to the project over  
24 the course of the development and post-marketing surveillance. On the other hand, the long-lived  
25 carbon radioisotope, C-14 ( $t_{1/2} = 5730$  years), has virtually no background noise which affords an  
26 exquisite signal to noise ratio that is utilized by drug discovery scientist to visualize, trace, and quantify  
27 drugs *in vivo*. Radiolabeled compounds are easily traced and quantified even after biochemical  
28 transformations since the detector response is independent of the structure of the compound;  
29 therefore, scintillation counting allows an accurate mass balance during (pre)clinical studies.<sup>3</sup> These  
30 qualities make C-14 the isotope of choice for absorption, distribution, metabolism and excretion  
31 studies (ADME), quantitative whole body autoradiography (QWBA) and environmental fate studies.<sup>4,3</sup>  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50 The labeled reagents used to prepare C-14 labeled compounds are highly expensive, for example the  
51 most readily available starting material Ba<sup>14</sup>CO<sub>3</sub> is around \$1850 per mmol. In addition, the synthetic  
52 chemistry required to incorporate the radiolabel leads to significant radioactive waste. This waste can  
53 be difficult and expensive to dispose of. Therefore, strategies which reduce radiochemical waste are  
54 of high importance. Hence, approaches including the late-stage incorporation of the radiolabel which  
55  
56  
57  
58  
59  
60

1  
2  
3 serve to minimize radiochemical waste typically require less radiochemical handling, thereby  
4 increasing the safety for the scientist.<sup>5</sup> Late-stage incorporation of the radiolabel also increases the  
5 overall efficiency of the carbon isotope incorporation.<sup>6</sup>  
6  
7  
8

9  
10 Carbonylation with carbon monoxide (CO) is a valuable technique for late-stage incorporation of  
11 carbon isotopes as it typically displays excellent functional group tolerance and can be applied to join  
12 two advanced intermediates.<sup>6,7</sup> Classical carbonylation methods utilize transition metal catalysis (i.e.  
13 Pd) to incorporate CO into complex drug-like molecules to afford ketones, carboxylic acids, esters, and  
14 amides.<sup>8</sup> However, most methods are only applicable with aryl or vinyl halides and triflate substrates  
15 for carbon labeling.<sup>9,10</sup> Most procedures describing the use of alkyl halides typically use an excess of  
16 CO.<sup>11</sup> While unlabeled CO is an inexpensive gas, <sup>14</sup>CO is expensive and thus preferably used as a limiting  
17 reagent. Sub-stoichiometric <sup>11</sup>CO carbonylation was achieved by Chow *et al*<sup>12</sup> using catalytic amounts  
18 of thermal radical initiator azobisisobutyronitrole (AIBN) (Scheme 1A). Despite the applicability of the  
19 AIBN catalyzed method on a wide range of functional groups, and compatibility with <sup>11</sup>CO (short lived  
20 isotope of carbon), AIBN presents major drawbacks due to its safety profile and toxic nature. A milder  
21 approach using photochemistry with visible-light and 2-3 atm CO has been applied for the  
22 functionalization of unactivated alkyl halides using aminocarbonylation<sup>13</sup> (Scheme 1B) and Pd-  
23 mediated cross-coupling with boronic acids<sup>14</sup> (Scheme 1C). Despite the synthetic utility of these  
24 methods and the advances they made in employing only moderate pressures of CO, in the context of  
25 isotope labeling further lowering the amount would be highly desirable. Inspired by the  
26 photochemistry works of Chow and Roslin, we explored the synthesis of amides *via* carbonylation of  
27 alkyl iodides with amines using *only* stoichiometric amounts of CO. The method could be successfully  
28 applied using palladium catalysis mediated by visible-light for late-stage aminocarbonylation.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Scheme 1 – Methodologies for carbonylation of unactivated alkyl halides.

## Results and discussion

At the onset of our investigations, we aimed to evaluate the reactivity of cyclohexyl iodide **1** and morpholine **2** under visible-light conditions and Pd-catalysis.<sup>13,14</sup> Unlabeled CO was used as the limiting reagent and was generated from 9-methylfluorene-9-carbonyl chloride (COgen), which provides a readily transferable, solid form of CO and has been used with labeled CO (<sup>13/14</sup>CO).<sup>6</sup> In order to limit

1  
2  
3 costs and generation of waste, the optimization of the procedure and part of the scope were  
4 performed using unlabeled COgen. We paid particular attention to the set-up of the reaction in order  
5 to ensure direct implementation of the protocol onto C-14 radiolabeling. The dual chamber system  
6 (COWare<sup>9</sup>, (Figure 1A)) was used as previously described. As COgen is moisture sensitive and  
7 undergoes hydrolysis, fresh batch of COgen was made before using.<sup>15</sup>  
8  
9

10  
11  
12 To facilitate the visible-light chemistry in a parallel fashion, a photoreactor was constructed (Figure  
13  
14  
15 1B-C). Blue LEDs surround a central compartment, which contains a heating block to enable the  
16 liberation of CO from COgen at 70 °C. The carbonylation chamber was kept at room temperature; a  
17 fan was used to circulate the air in the reactor to regulate the heat emitted from the LEDs. The setup  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000




Figure 1 – A Schematic view of the COWare, red represents the heating of the chamber and blue represents the blue visible-light irradiation. B top view of the elevated photoreactor. C Elevated photoreactor, enabling 6 reactions in parallel, with heating block in the middle to allow heating of Chamber B while Chamber A is kept at room temperature. D Single chamber photoreactor system.


The work began with an aminocarbonylation for the synthesis of alkyl amides. The COWare was loaded with cyclohexyl iodide **1**, 1.5 equiv of morpholine **2**, 5% Pd(PPh<sub>3</sub>)<sub>4</sub>, 1 equiv K<sub>2</sub>CO<sub>3</sub>, benzene:water (2:1, 3 mL) in the CO consuming chamber (chamber A), and the CO releasing chamber was loaded with 1 equiv COgen and the requisite reagents to release the CO (chamber B). Chamber B was heated to 70 °C for 24 h while chamber A was kept at room temperature and illuminated by blue LEDs, to give a

1  
2  
3 conversion of 44% to cyclohexyl(morpholino)methanone **3** (Table 1, entry 1). Motivated by this initial  
4  
5 success, we optimized the reaction with respect to amine (equiv), solvent, catalyst, and base.  
6  
7

8  
9 The systematic variation of reaction conditions enabled a better understanding of the factors  
10 governing the carbonylation process. Increasing the equivalents of morpholine to 3 equiv gave a yield  
11 of 64% (Table 1, entry 2). However, increasing morpholine beyond 3 equiv gave no further  
12 improvement (see Supporting Information, Table S1). To alleviate the poor solubility of CO in most  
13 organic solvents<sup>16</sup> the reaction volume was maximized, in conjunction with increased reagent  
14 concentrations. This led to a decrease in headspace, thus improving the CO partitioning into the  
15 solvent (Table 1, entry 3) to give a yield of 70%. A drop to 38% in (isolated) yield was observed when  
16 the reaction was performed on 1.2 mmol scale to give cyclohexyl(morpholino)methanone **3**. A similar  
17 result was observed by Roslin et al.<sup>14</sup> When the transformation was performed with <sup>13</sup>COgen on the  
18 same scale, no differences in isolated yield was observed (36%). The reaction was demonstrated to  
19 require light and Pd(PPh<sub>3</sub>)<sub>4</sub> (Table 1, entries 4-6). A catalyst screening was performed and Pd(PPh<sub>3</sub>)<sub>4</sub>  
20 was identified as the best catalyst. Due to the carcinogenic nature of benzene, finding an alternate  
21 solvent was imperative. Replacing benzene in the solvent system with toluene (Table 1, entry 7)  
22 showed a lower yield. Solvents with higher density than water were the most detrimental for the yield.  
23 Green solvents such as 2-MeTHF and CPME (Table 1, entries 8-10), showed comparable yield to  
24 benzene. 2-MeTHF showed good conversion with (61%) and without water (54%). A variety of bases,  
25 both organic and inorganic bases were shown to be effective. The time of the reaction was also  
26 monitored and maximum yield of the reaction was observed after 18 h (Table 1, entries 11-12).  
27 Selected results from our optimization experiments are summarized in the Supporting Information in  
28 Table S1.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Table 1 – Optimization of reaction conditions in the carbonylation chamber A



Entry	Solvent (volume [mL] <sup>a</sup> )	Catalyst (%)	Yield of <b>3</b> <sup>b</sup> (%)
<b>1</b>	Benzene/water 2:1 [3]	Pd(PPh <sub>3</sub> ) <sub>4</sub> (5)	44
<b>2</b>	Benzene/water 2:1 [3]	Pd(PPh <sub>3</sub> ) <sub>4</sub> (5)	64
<b>3<sup>c</sup></b>	Benzene/water 2:1 [5]	Pd(PPh <sub>3</sub> ) <sub>4</sub> (5)	70 (55)
<b>4<sup>c</sup></b>	Benzene/water 2:1 [5]	-	-
<b>5<sup>c</sup></b>	Benzene/water 2:1 [5]	PPh <sub>3</sub>	-
<b>6<sup>c,d</sup></b>	Benzene/water 2:1 [5]	Pd(PPh <sub>3</sub> ) <sub>4</sub> (5)	-
<b>7<sup>c</sup></b>	Toluene/water 2:1 [5]	Pd(PPh <sub>3</sub> ) <sub>4</sub> (5)	37
<b>8<sup>c</sup></b>	<b>2-MeTHF/water 2:1 [5]</b>	<b>Pd(PPh<sub>3</sub>)<sub>4</sub> (5)</b>	<b>81 (61)</b>
<b>9<sup>c</sup></b>	2-MeTHF [5]	Pd(PPh <sub>3</sub> ) <sub>4</sub> (5)	54
<b>10<sup>c</sup></b>	CPME/water 2:1 [5]	Pd(PPh <sub>3</sub> ) <sub>4</sub> (5)	58
<b>11<sup>c,e</sup></b>	2-MeTHF/water [5]	Pd(PPh <sub>3</sub> ) <sub>4</sub> (5)	39
<b>12<sup>c,f</sup></b>	2-MeTHF/water [5]	Pd(PPh <sub>3</sub> ) <sub>4</sub> (5)	62%


Standard conditions: Chamber A Catalyst (5 mol%), K<sub>2</sub>CO<sub>3</sub> (1 eq), solvent, iodocyclohexane (0.3 mmol, 1 eq), morpholine (1.5 eq). CO is produced in chamber B: Pd(dba)<sub>2</sub> (5 mol%), COgen (1 eq), toluene, P(t-Bu)<sub>3</sub> (0.05 eq), DIPEA (1.5 eq). <sup>a</sup> represents the volume in both chambers. <sup>b</sup> Determined by <sup>1</sup>H NMR using anisole (1 equiv) as internal standard. Number in parentheses represents isolated yield. <sup>c</sup> 0.6 mmol of iodocyclohexane and 3 eq morpholine. <sup>d</sup> no light. <sup>e</sup> reaction time 5h. <sup>f</sup> reaction time 18 h.

With the optimized conditions in hand (Table 1, entry 8), the scope of the amine coupling partner was investigated including primary, secondary, and aryl amines, to establish the versatility of this protocol and probe the limitations. The results are summarized in Scheme 2. Good yields were obtained for primary and cyclic secondary amines providing the amide products **3-6** in 37 to 61% yield. Yields of substituted piperazine (**4-5**) were lower than the model substrates. Cyclohexylamine, to our surprise did not show any product formation with water in the solvent system; interestingly, when employing anhydrous conditions the product **6** was afforded in 57% isolated yield. 2-Aminopyridine afforded an 18% yield for product **7**. Whereas aniline only showed a trace of product **19** on GC-MS. 2-Aminopyridine is more basic and therefore likely demonstrates the lower limit of nucleophilicity the reaction will tolerate. Substituted benzyl amine performed well as a substrate giving moderate yield of the desired product **8**.

1  
2  
3 Cyclohexyl iodide performed well with a range of amines. Therefore, the substrate scope was  
4 extended to a range of primary and tertiary iodides. Under the optimized conditions, the iodides were  
5 reacted with morpholine as the nucleophile. Tertiary iodides underwent a satisfactory reaction to  
6 afford the amide products (**9-10**) in moderate yield. Whereas 1-iodoadamantane returned the desired  
7 product **9** in higher yield compared to *tert*-butyl iodide. The less reactive 1-bromoadamantane  
8 afforded the expected product **9** in a 13% yield. Primary alkyl iodide, iodomethylcyclopentane, gave  
9 the product (**11**) with a yield of 41%. However, the lack of or low product (**12** and **23**) formation for  
10 iodopropane and (2-iodoethyl)benzene is indicative of the competing direct alkylation reaction, which  
11 is favored over the pathway towards carbonylation.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23


24 The generality of this method was further evaluated by performing the aminocarbonylation method  
25 with iodobenzene and, to our delight, morpholino(phenyl)methanone **13** was isolated with good  
26 yields. *Para* substituted aryl iodides, *tert*-butyl (4-iodobenzyl)carbamate, and 1-iodo-4-  
27 methoxybenzene were used to give good yields, 70% (**14**) and 69% (**15**), respectively.  
28  
29  
30  
31  
32  
33

34 Lastly, pharmaceutically relevant compounds were carbonylated with the optimized conditions.  
35 Praziquantel **18** and Bucinnazine analogue **16** gave a yield of respectively 13% and 19%. However,  
36 attempting synthesis of Bucinnazine **23** by carbonylation of isopropyl iodide and the corresponding  
37 piperazine gave predominantly the propylated piperazine. Adamantyl amide **17** was isolated with  
38 moderate yield; surprisingly, with aqueous conditions no product formation was observed.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Scheme 2 - Synthesis of alkyl amides by carbonylative coupling of alkyl iodides and amines. <sup>a</sup> 1.2 mmol scale. <sup>b</sup> Anhydrous conditions, 5 mL of 2-MeTHF was used in Chamber A. <sup>c</sup> 1-Bromoadamantane was used. <sup>d</sup> S<sub>N</sub>2 product was observed. <sup>e</sup> Product was hydrolyzed.

The utility of this method towards C-14 labeling was demonstrated using cyclohexyl iodide and morpholine. To reduce the radioactive waste, <sup>14</sup>COgen was diluted with unlabeled material, thus 5% <sup>14</sup>COgen was used with a specific activity of 0.110 TBq/mol. The result was in good agreement with the unlabeled carbonylation of cyclohexyl(morpholino)methanone **3** (Scheme 3) and the protocol was easily translated to a single photoreactor system (Figure 1D). [<sup>14</sup>C]Cyclohexyl(morpholino)methanone [<sup>14</sup>C]**3** was isolated with 50% yield with the expected specific activity within the error margin (Scheme 3).<sup>17</sup> Buccinazine analogue [<sup>14</sup>C]**16** was labeled to give 23% yield with the expected specific activity. To the best of our knowledge, no C-14 labeling procedures have been reported for either compounds.



26  
27  
28  
29

Scheme 3 - <sup>14</sup>CO reaction with model substrates, and drug-like compound. <sup>a</sup> Anhydrous conditions were used, 5 mL 2-MeTHF).

### 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

## Conclusion

In summary, a mild and versatile radical aminocarbonylation protocol was developed for the late-stage isotopic labeling by carbonylation with good substrate compatibility. By using visible-light irradiation and palladium catalysis, alkyl halides were coupled with amines at ambient temperature with stoichiometric amounts of CO. Moderate to low yields were obtained for late-stage labeling with labeled CO. It is noteworthy that the reaction was enabled by Pd(PPh<sub>3</sub>)<sub>4</sub>, which is cheap and readily available. Additionally, the use of COgen allowed easy translation between unlabeled reaction and labeled reaction. As for the substrate scope, a wide range of alkyl substrates can be carbonylated, such as the unactivated secondary and tertiary amines. Primary iodides, on the contrary, are difficult to achieve due to the competition with direct alkylation. To generalize the method, aryl iodides also reacted smoothly and were isolated with good yields; however, more investigations should be done to understand the mechanism and scope of this reaction. All in all, promising results have been achieved. These advances provide a powerful and broadly accessible tool for the labeling of functionalized alkyl amides.

## Experimental Section

**General Information.** *General Reactions.* All reagents were purchased from commercial suppliers and used without further purification, unless mentioned otherwise. Anhydrous solvents were purchased from Sigma Aldrich and stored under nitrogen atmosphere. 9-Methyl-9H-fluorene-9-carbonyl chloride and 9-Methylfluoren-9-[<sup>14</sup>C]-carbonyl chloride (respectively, COgen and <sup>14</sup>COgen) was prepared according to the procedure of Skrydstrup et al<sup>6</sup> and commercially available two chamber glassware apparatus (COware) was purchased from Sytracks and used for the carbonylation reactions. Yields are based on the COgen and refer to purified, isolated, homogenous product and spectroscopically pure material, unless stated otherwise.

*Reaction Setup.* All reactions were carried out under a nitrogen atmosphere and were magnetically stirred. Electric heating plates and DrySyn were used for elevated temperatures and stated temperatures corresponds to the external DrySyn temperature. Blue S6 LED strips (15 V, 15W/meter, 4.67m,  $\lambda = 465.2$  nm) were used, provided by LED Teknik Boras Sweden, no filters were used (see Supporting information for full LED report (Figure S1)). The distance between the COware (borosilicate glass) and the blue LED strips is between 2 and 4 cm, reactions were repeated on all positions, and comparable results were obtained. Concentration was performed on a rotary evaporator at 40 °C at appropriate pressure.

*Reaction mixture.* Crude reaction mixture was assayed by GCMS or LCMS and quantified by NMR with anisole as internal standard. LCMS analysis was performed on a Waters Acquity UPLC using either

- Method A: BEH C18 column (50mmx2.1mm, 1.7  $\mu$ m particles) with a 10-90% gradient over 2 or 4 min with MeCN-NH<sub>4</sub>/NH<sub>4</sub>CO<sub>3</sub>;
- Method B: BEH C18 column (50mmx2.1mm, 1.8  $\mu$ m particles) with a 10-90% gradient over 2 or 4 min with MeCN-formic acid and electrospray ionization.

1  
2  
3 **GCMS** (EI) analysis was performed on a 7890A GC system and 5975C inert MSD system equipped with  
4 an Agilent 19091S-433L (30 m x 250  $\mu$  x 0.25  $\mu$ m) capillary column using a gradient: 40-150  $^{\circ}$ C with a  
5 rate of 15  $^{\circ}$ C/min, followed by 150-300  $^{\circ}$ C with a rate of 60 $^{\circ}$ C/min, and electron impact ionization at  
6  
7  
8  
9  
10 **70 eV**.

11  
12 Thin layer chromatography was carried out using E. Merck silica glass plates (60F-254) with UV light  
13 (254 nm) and/or iodine vapor/potassium permanganate as the visualization agent.  
14


15  
16  
17  
18 *Purification.* Crude reaction mixtures were purified by either flash chromatography prepacked Isolute<sup>®</sup>  
19 SI columns or Biotage SNAP columns using a Biotage automated flash systems with UV detection or  
20 preparative reversed phase HPLC purifications using a Gilson 322 Pump equipped with a Gilson  
21 UV/Vis-152 lamp with an Xbridge<sup>™</sup> Prep C-18 10  $\mu$ m OBD<sup>™</sup> 19x250 mm column.  
22  
23  
24  
25

26  
27  
28 *Analysis.* <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Bruker AVANCE III system running at proton  
29 frequency of 500.1 MHz with a cryogenic probe or on a Bruker Avance Nanobay system at 400.13 MHz  
30 and processed with the NMR software MestreNova (Mestrelab Research SL). NMR experiments were  
31 run in CDCl<sub>3</sub> at 25 $^{\circ}$ C, unless stated otherwise. <sup>1</sup>H chemical shifts are referenced relative to the residual  
32 solvent peak at 7.26 ppm, and <sup>13</sup>C chemical shifts are referenced to 77.67 for CDCl<sub>3</sub>. Signals are listed  
33 in ppm, and multiplicity identified as s = singlet, br = broad, d = doublet, dt = doublet of a triplet, t =  
34 triplet, tt = triplet of a triplet, q = quartet, quin = quintet, h = hextet, m = multiplet; coupling constants  
35 in Hz; integration. <sup>13</sup>C NMR data is reported as with chemical shifts. For purity, quantitative NMR  
36 spectroscopy (qNMR) was performed with 2,3,5,6-tetrachloronitrobenzene (Tokyo Chemical Industry  
37 Co. Ltd. Japan, lot 242) (unless mentioned otherwise) as an internal calibrant in 0.6mL CDCl<sub>3</sub> (glass  
38 ampules, Sigma Aldrich).<sup>18</sup> Purity was calculated with the NMR processing software, MestreNova.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Accurate mass values were determined on a Waters Xevo Q-TOF mass spectrometer with an electro  
spray ion source in positive mode. Purity assays were also performed on the aforementioned LCMS  
and GCMS systems. Radiochemical purity was determined by HPLC using either

- Setup 1: Waters 2695 Separations module equipped with Waters x Select CSH C18 2.5  $\mu\text{m}$ , 3 x 100 mm column and with a radioactivity flow monitor using a Perkin-Elmer Radiomatic 500 TR with Ultima Gold cocktail. Gradient method was used for radiochemical purity determination with mobile phase A (water with 0.2% formic acid adjusted to pH 3) and B (95% MeCN/water 0.2% Formic acid pH 3) with gradient elution (50% B for 0-3 minutes, then ramp to 100% B over 17 min and hold at 100% B for 5 min).
- Setup 2: Waters Acquity UPLC with Waters Xbridge C18 3.5  $\mu\text{m}$ , 4.6 x 100mm column was used along with Perkin-Elmer TRI-CARB 2500 liquid scintillation analyser with Ultima Gold cocktail. Gradient method was used for radiochemical purity determination with mobile phase A (10mM  $\text{NH}_4\text{HCO}_3$  buffered with  $\text{NH}_4\text{OH}$ ) and B (MeCN) with gradient elution (5% for 0-3 minutes, then ramp to 95% over 22 min and hold at 95% for 5 minutes).

**General Procedures.** *General Procedure for Chamber B, CO Producing Chamber.* Chamber B was loaded in the following order  $\text{Pd}(\text{dba})_2$  (5%, 0.03 mmol), toluene (3 mL), tri-tert-butyl phosphane (5%, 0.03 mmol) and N,N-diisopropylethylamine (1.5 eq, 0.9 mmol). The chamber was sealed with Teflon-lined PTFE septa and stabilizing disc. The chamber is purged with  $\text{N}_2$ , after which COgen (1 eq, 0.6 mmol in toluene, 2 mL) is added and the chamber is stirred and heated to 70  $^\circ\text{C}$ .

*General Procedure for Amino Carbonylation Chamber A, CO Consuming Chamber.* To chamber A was added  $\text{Pd}(\text{PPh}_3)_4$  (5%, 0.03 mmol),  $\text{K}_2\text{CO}_3$ , (1 eq, 0.6 mmol), 2-MeTHF (3.5 mL), alkyl iodide (1 eq, 0.6 mmol), amine (3 eq, 1.8 mmol) and water (1.5 mL). The chamber was sealed with a Teflon lined PTFE septa and stabilizing disk. The chamber was purged for 5 minutes. The chamber was irradiated with visible blue light and stirred for 24 hours. The reaction mixture was extracted with  $\text{CH}_2\text{Cl}_2$  (3 x 10mL) over a phase separator and concentrated in vacuo, unless mentioned otherwise. Purification was performed using either manual system, Biotage automated normal purification system or reversed phase HPLC purification.



Preparation of *cyclohexyl(morpholino)methanone* **3** (CAS 29338-96-3).<sup>13</sup> Chamber A was loaded according to the general procedure with iodocyclohexane (78  $\mu\text{L}$ , 0.6 mmol) and morpholine (155  $\mu\text{L}$ , 1.80 mmol) in 2-MeTHF (3.5 mL) and water (1.5 mL) as solvent system. Chamber B was loaded according to the general procedure for CO releasing chamber. Purification was performed on a 25g SNAP column with 25% EtOAc in Heptane over 20 min. Fractions containing product were pooled and concentrated to give the desired product (72.2 mg, 61%). Data for **3**:  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  1.17 – 1.32 (m, 3H), 1.52 (m, 2H), 1.70 (d,  $J = 12.94$  Hz, 5H), 2.42 (tt,  $J = 3.41, 3.41, 11.58, 11.58$  Hz, 1H), 3.44 – 3.71 (m, 8H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (100.6 MHz,  $\text{CDCl}_3$ )  $\delta$  174.6, 67.0, 66.8, 45.8, 41.9, 40.2, 29.3, 25.75, 25.74. NMR purity assay: 95%.

#### **$[^{13}\text{C}]\mathbf{3}$ – 1.2 mmol**


Preparation of *cyclohexyl(morpholino)methanone*  $[^{13}\text{C}]\mathbf{3}$ . Chamber A was loaded according to the general procedure with iodocyclohexane (155  $\mu\text{L}$ , 1.2 mmol), morpholine (311  $\mu\text{L}$ , 3.6 mmol),  $\text{K}_2\text{CO}_3$  (166 mg, 1.2 mmol),  $\text{Pd}(\text{PPh}_3)_4$  (69.3 mg, 0.06 mmol) in 2-MeTHF (3.5 mL) and water (1.5 mL) as solvent system. Chamber B was loaded according to the general procedure CO releasing chamber with  $\text{Pd}(\text{dba})_2$  (34.5 mg, 0.06 mmol),  $\text{P}(t\text{-Bu})_3$  (60  $\mu\text{L}$ , 0.06 mmol),  $\text{N,N}$ -diisopropylamine (315  $\mu\text{L}$ , 1.81 mmol) in toluene (5 mL), and at last  $[^{13}\text{C}]\text{COgen}$  (292 mg, 1.2 mmol). Purification was performed on 25g SNAP column with 0-60% EtOAc in Heptane. Fractions containing product were pooled and concentrated to give the desired product (86.3 mg, 38%). NMR purity assay: 96.1%.

#### ****3** – 1.2 mmol**


Preparation of *cyclohexyl(morpholino)methanone* **3**. Chamber A was loaded according to the general procedure with iodocyclohexane (155  $\mu\text{L}$ , 1.2 mmol), morpholine (311  $\mu\text{L}$ , 3.6 mmol),  $\text{K}_2\text{CO}_3$  (166 mg, 1.2 mmol),  $\text{Pd}(\text{PPh}_3)_4$  (69.3 mg, 0.06 mmol) in 2-MeTHF (3.5 mL) and water (1.5 mL) as solvent system.



Chamber B was loaded according to the general procedure CO releasing chamber with Pd(dba)<sub>2</sub> (34.5 mg, 0.06 mmol), P(*t*-Bu)<sub>3</sub> (60 μL, 0.06 mmol), N,N-diisopropylamine (315 μL, 1.81 mmol) in toluene (1 mL), and at last COgen (291 mg, 1.2 mmol, 0.3M, 4 mL). Purification was performed on 25g SNAP column with 0-60% EtOAc in Heptane. Fractions containing product were pooled and concentrated to give the desired product (85 mg, 36%). NMR purity assay: 96.6%.




*Preparation of [14C]cyclohexyl(morpholino)methanone 3.* Chamber A was loaded according to the general procedure and reaction procedure for **3**. Chamber B was loaded according to the general procedure for CO releasing chamber COgen (129 mg, 0.57 mmol) and [14C]COgen (65.7 MBq, 0.03 mmol) was used. Purification was performed on a 20g Flash Si column with 25% EtOAc in Heptane. Fractions containing product were pooled and concentrated in vacuo to give the desired product (32.96 MBq, 0.117 TBq/mol, 50%). Radio-HPLC (setup 1) 98.87%.




*Preparation of tert-butyl 4-(cyclohexanecarbonyl)piperazine-1-carboxylate 4* (CAS 1328099-31-5). Chamber A was loaded according to general procedure iodocyclohexane (78 μL, 0.6 mmol) and tert-butyl piperazine-1-carboxylate (343.2 mg, 1.84 mmol). Chamber B was loaded according to the CO releasing chamber. Purification was performed on a 10g Flash Si column with 25% EtOAc in n-Heptane. Fractions containing product were pooled and concentrated in vacuo to give the desired product (88.7 mg, 50%). Data for **4**: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.23 – 1.28 (m, 2H), 1.44 – 1.59 (m, 11H), 1.65 – 1.84 (m, 5H), 2.44 (tt, J = 11.6, 3.3 Hz, 1H), 3.31 – 3.65 (m, 8H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>) δ 174.9,


1  
2  
3 154.7, 80.4, 77.5, 77.4, 77.2, 76.8, 45.3, 43.9, 41.5(broad peaks due to conformation change), 40.6,  
4  
5 29.5, 28.5, 25.96, 25.94. NMR purity assay 90%. HRMS (ESI-TOF) m/z: [M+H]<sup>+</sup> Calcd for C<sub>16</sub>H<sub>28</sub>N<sub>2</sub>O<sub>3</sub>  
6  
7 297.2178; Found 297.2195.  
8  
9



21 *Preparation of cyclohexyl(4-(2-methoxyphenyl)piperazin-1-yl)methanone 5.* Chamber A was loaded  
22 according to the general procedure with iodocyclohexane (1 eq, 78  $\mu$ L, 0.6 mmol) and 1-(2-  
23 methoxyphenyl)piperazine hydrochloride (2.52 eq, 346 mg, 1.51 mmol). Chamber B was loaded  
24 according to the general procedure for the CO releasing chamber. Purification was performed *via* HPLC  
25 (5-70% MeCN – 0.1% TFA in water over 20 min, wavelength 220nm, 15mL/min). Fractions containing  
26 product were pooled and lyophilized to give product as TFA salt. The product was partitioned in 5 mL  
27 CH<sub>2</sub>Cl<sub>2</sub> and 5 mL Na<sub>2</sub>CO<sub>3</sub>. The layers are separated over a phase separator. The aqueous layer was  
28 washed with CH<sub>2</sub>Cl<sub>2</sub> (5 x 5mL). The organic layers were combined and concentrated to give the free  
29 product (67.1 mg, 37%). Data for **5**: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.23 – 1.37 (m, 3H), 1.5 – 1.63 (m, 2H),  
30 1.66 – 1.86 (m, 6H), 2.52 (tt, J = 3.31, 3.31, 11.55, 11.55 Hz, 1H), 3.05 (dt, J = 4.78, 4.78, 17.63 Hz, 4H),  
31 3.67 – 3.73 (m, 2H), 3.79 – 3.84 (m, 2H), 3.89 (s, 3H), 6.87 – 6.97 (m, 3H), 7 – 7.1 (m, 1H). <sup>13</sup>C{<sup>1</sup>H} NMR  
32 (101 MHz, CDCl<sub>3</sub>)  $\delta$  174.6, 152.2, 123.6, 121.0, 118.5, 111.3, 77.3, 77.2, 77.0, 76.7, 55.4, 51.3, 50.7,  
33 45.6, 41.7, 40.4, 29.4, 25.89, 25.86. A peak at 140 ppm missing, however strong correlation on HMBC  
34 suggests it is a quaternary aromatic carbon. NMR purity assay: 96.7%. LCMS (Method B, 4min): 303.0  
35 [M+H]<sup>+</sup>, rt 2.07 min (100%). HRMS (ESI-TOF) m/z: [M+H]<sup>+</sup> Calcd for C<sub>18</sub>H<sub>26</sub>N<sub>2</sub>O<sub>2</sub> 303.2072; Found  
36 303.2070.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




*Preparation of N-cyclohexylcyclohexanecarboxamide 6* (CAS 7474-36-4).<sup>12</sup> Chamber A was loaded according to general procedure iodocyclohexane (78  $\mu$ L, 0.60 mmol) and cyclohexanamine (206  $\mu$ L, 1.80 mmol), 5 mL 2-methyl THF. Chamber B was loaded according to the CO releasing chamber. The reaction mixture concentrated *in vacuo*. Purification was performed on a 10g Flash Si column with 25% EtOAc in n-Heptane. Fractions containing product were pooled and concentrated *in vacuo* to give the desired product (72.1 mg, 57%). Data for **6**:  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  1.02 – 1.48 (m, 11H), 1.57 – 1.94 (m, 10H), 2.01 (tt,  $J = 3.40, 3.40, 11.83, 11.83$  Hz, 1H), 3.68 – 3.82 (m, 1H), 5.24 (s, 1H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  175.1, 77.2, 77.0, 76.8, 47.7, 45.8, 33.3, 29.8, 25.8, 25.6, 24.9. NMR purity assay 96.1%. GCMS: 209.2 [M], rt 9.83 min (100%).




*Preparation of N-(pyridin-2-yl)cyclohexanecarboxamide 7* (CAS 68134-77-0).<sup>19</sup> Chamber A was loaded according to general procedure iodocyclohexane (78  $\mu$ L, 0.6 mmol) and pyridine-2-amine (165.2 mg, 1.76 mmol). Chamber B was loaded according to the CO releasing chamber. Purification was performed on a 10g SNAP column with 8-66% EtOAc in n-Heptane. Fractions containing product were pooled and concentrated *in vacuo*. The obtained product was further purified on a 10g isolate SI column. Fractions containing product were pooled and concentrated *in vacuo* to give the product (22.4 mg, 18%). Data for **7**:  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  1.25 – 1.38 (m, 3H), 1.49 – 1.62 (m, 2H), 1.71 (d,  $J = 10.9$  Hz, 1H), 1.79 – 1.88 (m, 2H), 2.01 (d,  $J = 13.0$  Hz, 2H), 2.38 (t,  $J = 12.1$  Hz, 1H), 7.14 (t,  $J = 6.6$  Hz, 1H), 7.87 (t,  $J = 7.6$  Hz, 1H), 8.21 (d,  $J = 5.1$  Hz, 1H), 8.43 (d,  $J = 8.5$  Hz, 1H), 9.35 (s, 1H).  $^{13}\text{C}\{^1\text{H}\}$

1  
2  
3 NMR (100.59 MHz, CDCl<sub>3</sub>) δ 176.08, 150.8, 142.6, 142.1, 119.4, 115.8, 46.5, 29.4, 25.7, 25.3. NMR  
4  
5 purity assay 88%. LCMS (Method B, 4 min): 205.07 [M+H]<sup>+</sup>, rt 1.35 min (100%).  
6  
7



8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19 *Preparation of tert-butyl 4-(2-(cyclohexanecarboxamidomethyl)phenyl)piperazine-1-carboxylate 8.*


20 Chamber A was loaded according to the general procedure with iodocyclohexane (1 eq, 78 μL, 0.6  
21 mmol) and tert-butyl 4-(2-(aminomethyl)phenyl)piperazine-1-carboxylate (3 eq, 522.5 mg, 1.79  
22 mmol). Chamber B was loaded according to the general procedure for CO releasing chamber.  
23 Purification was performed on a 10g SNAP column with EtOAc in Heptane (0-70%) over 20 min.  
24 Fractions containing product were pooled and concentrated to give the desired product (70.2 mg,  
25 29%). Data for **8**: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.28 (m, 3H), 1.39 – 1.52 (m, 11H), 1.64 – 1.72 (m, 1H),  
26 1.76 – 1.85 (m, 2H), 1.86 – 1.95 (m, 2H), 2.12 (tt, J = 3.48, 3.48, 11.73, 11.73 Hz, 1H), 2.82 – 2.92 (m,  
27 4H), 3.58 (t, J = 4.90, 4.90 Hz, 4H), 4.55 (d, J = 5.57 Hz, 2H), 6.19 (t, J = 4.34, 4.34 Hz, 1H), 7.07 – 7.15  
28 (m, 2H), 7.24 – 7.3 (m, 2H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>, 26°C) δ 175.73, 154.74, 151.03, 133.1, 129.2,  
29 128.4, 124.6, 120.2, 79.9, 77.3, 77.0, 76.7, 52.5, 45.7, 39.6, 29.8, 28.4, 25.8. NMR purity assay: 98.9%.  
30 HRMS (ESI-TOF) m/z: [M+H]<sup>+</sup> Calcd for C<sub>23</sub>H<sub>35</sub>N<sub>3</sub>O<sub>3</sub> 402.2757; Found 402.2761.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47




54 *Preparation of adamantan-1-yl(morpholino)methanone 9 (CAS 22508-50-5).<sup>12</sup>* Chamber A was loaded  
55 according to general procedure 1-iodoadamantane (158.4 mg, 0.60 mmol) and morpholine (3 eq, 155  
56 μL, 1.8 mmol). Chamber B was loaded according to the CO releasing chamber. Purification was  
57  
58  
59  
60

1  
2  
3 performed on a 10g Flash Si column with 25% EtOAc in n-Heptane. Fractions containing product were  
4  
5 pooled and concentrated in vacuo to give the desired product (57.9 mg, 39%). Data for **9**:  $^1\text{H}$  NMR (400  
6 MHz,  $\text{CDCl}_3$ )  $\delta$  1.66 – 1.78 (m, 6H), 1.97 – 2.01 (m, 6H), 2.02 – 2.07 (m, 3H), 3.63 – 3.73 (m, 8H).  $^{13}\text{C}\{^1\text{H}\}$   
7  
8 NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  175.9, 77.2, 77.0, 76.8, 67.1, 46.0, 41.7, 39.0, 36.6, 28.5, 28.3. NMR purity  
9  
10 assay 92%. LCMS (Method B, 4 min): 250.1  $[\text{M}+\text{H}]^+$ , rt 1.77 min (100%).


11  
12  
13  
14  
15 *Preparation of adamantan-1-yl(morpholino)methanone 9* (CAS 22508-50-5) *from 1-*  
16  
17 *bromoadamantane*. Chamber A was loaded according to general procedure 1-bromoadamantane  
18  
19 (137.5 mg, 0.64 mmol) and morpholine (3 eq, 155  $\mu\text{L}$ , 1.8 mmol). Chamber B was loaded according to  
20  
21 the CO releasing chamber. Purification was performed on a 20g Flash Si column with 0-25% EtOAc in  
22  
23 n-Heptane. Fractions containing product were pooled and concentrated in vacuo to give the desired  
24  
25 product (19.3 mg, 13%). NMR purity assay 88%.




36 *Preparation of 2,2-dimethyl-1-morpholinopropan-1-one 10* (CAS 70414-49-2). Chamber A was loaded  
37  
38 according to general procedure 2-iodo-2-methylpropane (72  $\mu\text{L}$ , 0.60 mmol) and morpholine (155  $\mu\text{L}$ ,  
39  
40 1.80 mmol). Chamber B was loaded according to the CO releasing chamber. Purification was  
41  
42 performed on a 20g Flash Si column with 0-25% EtOAc in n-Heptane. Fractions containing product  
43  
44 were pooled and concentrated in vacuo to give the translucent crystals (15.8 mg, 15%). Data for **10**:  
45  
46  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  1.26 (s, 9H), 3.65 (d,  $J = 7.3$  Hz, 8H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  176.6,  
47  
48 77.5, 77.2, 76.9, 67.0, 45.9, 38.7, 28.4. NMR purity assay 99%. HRMS (ESI-TOF)  $m/z$ :  $[\text{M}+\text{H}]^+$  Calcd for  
49  
50  $\text{C}_9\text{H}_{17}\text{NO}_2$  172.1337; Found 172.1326.




1  
2  
3 *Preparation of 2-cyclopentyl-1-morpholinoethan-1-one 11.* Chamber A was loaded according to the  
4 general procedure (iodomethyl)cyclopentane (127.9 mg, 0.61 mmol) and morpholine (155  $\mu$ L, 1.80  
5 mmol). Chamber B was loaded according to the general procedure. Purification was performed on a  
6 10g SI column with 25% EtOAc in Heptane. Fractions containing product were pooled and  
7 concentrated to give product (42.3 mg, 36%). Data for **11**:  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  1.04 – 1.19 (m,  
8 2H), 1.45 – 1.66 (m, 4H), 1.74 – 1.89 (m, 2H), 2.11 – 2.28 (m, 1H), 2.31 (d,  $J = 7.4$  Hz, 2H), 3.38 – 3.51  
9 (m, 2H), 3.53 – 3.68 (m, 6H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  171.7, 77.5, 77.2, 76.8, 67.2, 66.9, 46.3,  
10 42.0, 39.2, 36.8, 32.9, 25.1. NMR purity assay 85%. LCMS (Method A, 4 min): 198  $[\text{M}+\text{H}]^+$ , rt 1.16 min  
11 (100%). HRMS (ESI-TOF)  $m/z$ :  $[\text{M}+\text{H}]^+$  Calcd for  $\text{C}_{11}\text{H}_{19}\text{NO}_2$  198.1494; Found 198.1493.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23




31 *Preparation of 1-morpholino-3-phenylpropan-1-one 12.* Chamber A was loaded according to general  
32 procedure (2-iodoethyl)benzene (87  $\mu$ L, 0.60 mmol) and morpholine (155  $\mu$ L, 1.80 mmol). Chamber B  
33 was loaded according to the CO releasing chamber. Purification was performed on a 25g SNAP column  
34 with EtOAc in Heptane (2-100% EtOAc). Fractions were pooled, concentrated and subjected to HPLC  
35 purification (5-75% MeCN - 0.2%  $\text{NH}_3$  in  $\text{H}_2\text{O}/\text{MeCN}$  (95:5) over 15 min, wavelength 220 nm, 15  
36 mL/min). Fractions containing product were pooled and lyophilized to give the desired product (10.9  
37 mg, 8%). Data for **12**:  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  2.58 – 2.66 (m, 2H), 2.94 – 3.03 (m, 2H), 3.31 – 3.41  
38 (m, 2H), 3.47 – 3.56 (m, 2H), 3.62 (s, 4H), 7.18 – 7.24 (m, 3H), 7.27 – 7.32 (m, 2H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (101  
39 MHz,  $\text{CDCl}_3$ )  $\delta$  171.0, 141.2, 128.7, 128.6, 126.4, 77.5, 77.2, 76.8, 67.0, 66.6, 46.1, 42.1, 35.0, 31.6.  
40 LCMS (Method A, 4min): 220  $[\text{M}+\text{H}]^+$ , rt 1.13 min (100%). HRMS (ESI-TOF)  $m/z$ :  $[\text{M}+\text{H}]^+$  Calcd for  
41  $\text{C}_{13}\text{H}_{17}\text{NO}_2$  220.1137; found 220.1135.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Preparation of morpholino(phenyl)methanone **13** (CAS 1468-28-6).<sup>20</sup> Chamber A was loaded according to general procedure with iodobenzene (1 eq, 67  $\mu$ L, 0.6 mmol) and morpholine (3 eq, 155  $\mu$ L, 1.8 mmol). Chamber B was loaded according to the CO releasing chamber. Purification was performed *via* HPLC (5-70% MeCN – 0.1% TFA in water over 20 min, wavelength 220nm, 15mL/min). Fractions containing product were pooled and lyophilized to give the desired product (69.7 mg, 61%). Data for **13**: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  3.25 – 3.87 (m, 8H), 7.3 – 7.41 (m, 5H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  170.3, 135.3, 129.8, 128.5, 127.0, 77.5, 77.2, 76.8, 66.8, 48.1, 42.5. NMR purity assay: 98.1%. LCMS (Method B, 4 min): 192.01 [M+H]<sup>+</sup>, rt 0.87 min (100%).



Preparation of tert-butyl (4-(morpholine-4-carbonyl)benzyl)carbamate **14** (CAS 1110964-59-4). Chamber A was loaded according to general procedure tert-butyl (4-iodobenzyl)carbamate (204.5 mg, 0.61 mmol) and morpholine (155  $\mu$ L, 1.80 mmol). Chamber B was loaded according to the CO releasing chamber. Purification was performed on a 20g Isolute SPE Si column with 25%-100% EtOAc in n-Heptane. Fractions containing product were pooled and concentrated in vacuo to give the desired product (133.9 mg, 70%). Data for **14**: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.46 (s, 9H), 3.2 – 3.99 (m, 8H), 4.33 (d, J = 5.7 Hz, 2H), 4.92 (s, 1H), 7.28 – 7.41 (m, 4H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  170.3, 156.0, 141.2, 134.4, 127.6, 127.5, 79.9, 77.5, 77.4, 77.2, 76.8, 67.0, 44.4, 28.5. NMR purity assay: 88%. HRMS (ESI-TOF) m/z: [M+H]<sup>+</sup> Calcd for C<sub>17</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub> 321.1814; Found 321.1818.




*Preparation of (4-methoxyphenyl)(morpholino)methanone 15* (CAS 7504-58-7). Chamber A was loaded according to general procedure 1-iodo-4-methoxybenzene (139 mg, 0.59 mmol) and morpholine (155  $\mu$ L, 1.80 mmol). Chamber B was loaded according to the CO releasing chamber. Purification was performed on a 20g Flash Si column with 40%-100% EtOAc in n-Heptane. Fractions containing product were pooled and concentrated in vacuo to give the desired product (92.8 mg, 70%). Data for **15**:  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  3.66 (d,  $J = 17.5$  Hz, 8H), 3.82 (s, 3H), 6.82 – 6.98 (m, 2H), 7.29 – 7.44 (m, 2H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  170.5, 161.0, 129.3, 127.5, 113.9, 77.5, 77.2, 76.8, 67.0, 55.5. NMR purity assay: 83.6%. HRMS (ESI)  $m/z$ :  $[\text{M}+\text{H}]^+$  Calcd for  $\text{C}_{12}\text{H}_{15}\text{NO}_3$  222.1130; Found 222.1112.




*Preparation of 1-adamantyl-[4-[(E)-cinnamyl]piperazin-1-yl]methanone 16* (CAS 60277-86-3).<sup>21</sup> Chamber A was loaded according to the general procedure with 1-iodoadamantane (157 mg, 0.60 mmol) and trans 1-cinnamylpiperazine (364 mg, 1.80 mmol), 5 mL 2-MeTHF. Chamber B was loaded according to the general procedure. Purification was performed *via* HPLC (35-95% MeCN – 0.2%  $\text{NH}_3$  in  $\text{H}_2\text{O}/\text{MeCN}$  (95:5) over 25 min, wavelength 250 nm, 20 mL/min). Fractions were pooled and lyophilized to give product as brown sticky oil (40.8 mg, 19%). Data for **16**:  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  1.66 – 1.77 (m, 6H), 1.95 – 2.06 (m, 9H), 2.42 – 2.53 (m, 4H), 3.12 – 3.19 (m, 2H), 3.64 – 3.81 (m, 4H), 6.25 (dt,  $J = 15.8, 6.8$  Hz, 1H), 6.52 (d,  $J = 15.9$  Hz, 1H), 7.2 – 7.26 (m, 1H), 7.28 – 7.34 (m, 2H), 7.35 – 7.39 (m, 2H).  $^{13}\text{C}\{^1\text{H}\}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  175.8, 136.9, 133.6, 128.7, 127.8, 126.5, 126.1, 77.5, 77.2, 76.8, 61.1, 53.6, 45.4, 41.8, 39.2, 36.8, 28.6. NMR purity assay: 87.7%. LCMS: 365  $[\text{M}+\text{H}]^+$ , rt 2.63 min (base 4 min) (87%). HRMS (ESI-TOF)  $m/z$ :  $[\text{M}+\text{H}]^+$  Calcd for  $\text{C}_{24}\text{H}_{32}\text{N}_2\text{O}$  365.2593; Found 365.2589.






Preparation of 1-adamantyl-[4-[(E)-cinnamyl]piperazin-1-yl]methanone **[<sup>14</sup>C]16**. Chamber A was loaded according to the general procedure with 1-iodoadamantane (157 mg, 0.60 mmol) and trans 1-cinnamylpiperazine (384 mg, 1.90 mmol), 5 mL 2-MeTHF. Chamber B was loaded according to the general procedure for CO releasing chamber COgen (128.5 mg, 0.57 mmol) and [<sup>14</sup>C]COgen (69.06 MBq, 0.03 mmol) was used. Purification was performed *via* HPLC (60-80% MeCN – 0.2% NH<sub>3</sub> in H<sub>2</sub>O/MeCN (95:5) over 15 min, wavelength 250 nm, 20 mL/min). Fractions were pooled and lyophilized to give product as light-yellow sticky oil (14.31 MBq, 0.106 TBq/mol, 23%). Radio-HPLC (setup 2) 97.48%.




Preparation of Adamantan-1-yl(piperidin-1-yl)methanone **17** (CAS 22508-49-2).<sup>12</sup> Chamber A was loaded according to general procedure 1-iodoadamantane (157 mg, 0.60 mmol) and piperidine (178 μL, 1.80 mmol). Chamber B was loaded according to the CO releasing chamber. Purification was performed on a 25g SNAP column with 0-25% EtOAc in n-Heptane. Fractions containing product were pooled and concentrated in vacuo to give the translucent crystals (42 mg, 28.3). Data for **17**: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.49 – 1.59 (m, 4H), 1.61 – 1.67 (m, 2H), 1.69 – 1.77 (m, 6H), 1.97 – 2.07 (m, 9H), 3.52 – 3.67 (m, 4H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>) δ 175.7, 77.5, 77.2, 76.8, 46.6, 41.9, 39.2, 36.9, 28.7, 26.5, 25.0. NMR purity assay: 96%.



*Preparation of 2-(cyclohexanecarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one*

**18** (Praziquantel, CAS 55268-74-1).<sup>22</sup> Chamber A was loaded according to the general procedure with 1-iodocyclohexane (78  $\mu$ L, 0.60 mmol) and 1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one (350.9 mg, 1.73 mmol). Chamber B was loaded according to the general procedure. Purification was performed on a 25g SNAP column with 12-100% EtOAc in n-Heptane. Fractions containing product were pooled and concentrated in vacuo to give product (53.5 mg, 28.5%). This was subjected to recrystallization by dissolution in warm EtOH, and then stored in the freezer. Filtration gave fluffy crystals (24.8 mg, 13%). Data for **18**: <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  1.23 – 1.42 (m, 3.3H, major + minor), 1.48 – 1.65 (m, 2H, major + minor), 1.7 – 1.9 (m, 5.4H, major + minor), 2.43 – 2.62 (m, 1H, major + minor), 2.76 – 3.05 (m, 4H), 3.27 (t, J = 11.7 Hz, 0.21H, minor), 3.88 (d, J = 18.5 Hz, 0.21H, minor), 4.10 (d, J = 17.4 Hz, 0.76H, major), 4.39 (d, J = 12.8 Hz, 0.21H, minor), 4.49 (d, J = 17.4 Hz, 0.77H, major), 4.75 – 4.96 (m, 2.3H, major + minor), 5.18 (d, J = 13.1 Hz, 0.76H, major), 7.15 – 7.25 (m, 1.3H), 7.27 – 7.36 (m, 2.7H). <sup>13</sup>C{<sup>1</sup>H} NMR (126 MHz, CDCl<sub>3</sub>)  $\delta$  174.8 (major), 174.3 (minor), 165.6 (minor), 164.4 (major), 135.5 (minor), 134.7 (major), 132.8 (major), 132.1 (minor), 129.7 (minor), 129.3 (major), 127.7 (minor), 127.5 (major), 127.0, 125.5 (major), 125.2 (minor), 55.8 (minor), 55.0 (major), 49.6 (minor), 49.0 (major), 46.3 (minor), 45.2 (major), 40.8, 39.1 (major), 38.7 (minor), 29.5 (minor), 29.3 (major), 29.2 (minor), 29.0 (major), 28.9 (minor), 28.7 (major), 25.7. NMR purity assay: 96.6%. HRMS (ESI-TOF) m/z: [M+H]<sup>+</sup> Calcd for C<sub>19</sub>H<sub>24</sub>N<sub>2</sub>O<sub>2</sub> 313.1916; Found 313.1908.



1  
2  
3 *Preparation of 1-(4-cinnamylpiperazin-1-yl)butan-1-one* **23** (Bucinnazine, CAS 17719-89-0).<sup>23</sup> Chamber  
4  
5 A was loaded according to the general procedure with 1-iodopropane (59  $\mu$ L, 0.60 mmol) and trans 1-  
6  
7 cinnamylpiperazine (364 mg, 1.80 mmol), 5 mL 2-MeTHF. Chamber B was loaded according to the  
8  
9 general procedure. Purification was performed *via* HPLC (30-90% MeCN – 0.2% NH<sub>3</sub> in H<sub>2</sub>O/MeCN  
10  
11 (95:5) over 25 min, wavelength 250 nm, 20 ml/min. Fractions were pooled and lyophilized to give  
12  
13 product (5.37 mg, 3%). Data for **23**: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.97 (t, J = 7.4 Hz, 3H), 1.67 (h, J = 7.4  
14  
15 Hz, 2H), 2.30 (t, J = 7.5 Hz, 2H), 2.97 (broad s, 4H), 3.39 – 4.15 (m, 6H), 6.27 (dt, J = 15.4, 7.3 Hz, 1H),  
16  
17 6.69 (d, J = 15.8 Hz, 1H), 7.28 – 7.43 (m, 5H). <sup>13</sup>C{<sup>1</sup>H} NMR (126 MHz, CDCl<sub>3</sub>)  $\delta$  171.4, 128.8, 126.9, 77.3,  
18  
19 77.0, 76.8, 59.8, 51.5, 43.2, 39.1, 34.9, 18.6, 13.9.  
20  
21  
22  
23

#### 24 **Associated Content**

#### 25 **Supporting Information**

26  
27  
28  
29  
30 Led Report, General Procedure for Optimization of Amino Carbonylation Reaction, <sup>1</sup>H and <sup>13</sup>C NMR  
31  
32 spectra of the amide products and LCMS chromatograms of the [<sup>14</sup>C]-labeled amide products, NMR  
33  
34 data. This material is available free of charge.  
35  
36

#### 37 **Author Information**

##### 38 *Corresponding Author*

39  
40  
41  
42  
43 \*Email: [Malvika.Sardana@astrazeneca.com](mailto:Malvika.Sardana@astrazeneca.com)  
44  
45

##### 46 ORCID

47  
48  
49 Malvika Sardana: <https://orcid.org/0000-0002-6838-4392>  
50

51  
52 Joakim Bergman: <https://orcid.org/0000-0003-0413-1756>  
53

54  
55 Lee P Kingston: <https://orcid.org/0000-0002-6845-6894>  
56

57  
58 Magnus Schou : <https://orcid.org/0000-0002-4314-2418>  
59  
60

1  
2  
3 Davide Audisio: <https://orcid.org/0000-0002-6234-3610>  
4  
5

6 Charles S Elmore: <https://orcid.org/0000-0001-7434-8307>  
7  
8

### 9 **Acknowledgement**

10  
11  
12 This project has received funding from the European Union's Horizon 2020 research and innovation  
13 program under the Marie Skłodowska-Curie grant agreement No 675071.  
14  
15

### 16 **References**

- 17  
18  
19  
20 (1) Krauser, J. A. A Perspective on Tritium versus Carbon-14: Ensuring Optimal Label Selection in  
21 Pharmaceutical Research and Development. *J. Label. Compd. Radiopharm.* **2013**, *56* (9–10),  
22 441–446. <https://doi.org/10.1002/jlcr.3085>.  
23  
24  
25  
26  
27 (2) Stokvis, E.; Rosing, H.; Beijnen, J. H. Stable Isotopically Labeled Internal Standards in  
28 Quantitative Bioanalysis Using Liquid Chromatography/mass Spectrometry: Necessity or Not?  
29 *Rapid Commun. Mass Spectrom.* **2005**, *19* (3), 401–407. <https://doi.org/10.1002/rcm.1790>.  
30  
31  
32  
33  
34 (3) Elmore, C. S. The Use of Isotopically Labeled Compounds in Drug Discovery. *Annual Reports in*  
35 *Medicinal Chemistry*. Elsevier 2009, pp 515–534. [https://doi.org/10.1016/S0065-](https://doi.org/10.1016/S0065-7743(09)04425-X)  
36 [7743\(09\)04425-X](https://doi.org/10.1016/S0065-7743(09)04425-X).  
37  
38  
39  
40  
41  
42 (4) Isin, E. M.; Elmore, C. S.; Nilsson, G. N.; Thompson, R. A.; Weidolf, L. Use of Radiolabeled  
43 Compounds in Drug Metabolism and Pharmacokinetic Studies. *Chem. Res. Toxicol.* **2012**, *25*  
44 (3), 532–542. <https://doi.org/10.1021/tx2005212>.  
45  
46  
47  
48  
49 (5) Voges, R.; Heys, J. R.; Moenius, T. *Preparation of Compounds Labeled with Tritium and*  
50 *Carbon-14*; John Wiley & Sons, Ltd: West Sussex, 2009.  
51  
52  
53  
54 (6) Lindhardt, A. T.; Simonssen, R.; Taaning, R. H.; Gøgsig, T. M.; Nilsson, G. N.; Stenhagen, G.;  
55 Elmore, C. S.; Skrydstrup, T. <sup>14</sup>Carbon Monoxide Made Simple - Novel Approach to the  
56 Generation, Utilization, and Scrubbing of <sup>14</sup>carbon Monoxide. *J. Label. Compd. Radiopharm.*  
57  
58  
59  
60

- 1  
2  
3 **2012**, 55 (11), 411–418. <https://doi.org/10.1002/jlcr.2962>.
- 4  
5  
6 (7) Elmore, C. S.; Dean, D. C.; Melillo, D. G. A Convenient Method for [<sup>14</sup>C]Carbonylation  
7  
8 Reactions. *J. Labelled Comp. Radiopharm.* **2000**, No. 43, 1135–1144.
- 9  
10  
11 (8) Nielsen, D. U.; Neumann, K. T.; Lindhardt, A. T.; Skrydstrup, T. Recent Developments in  
12  
13 Carbonylation Chemistry Using [<sup>13</sup>C]CO, [<sup>11</sup>C]CO, and [<sup>14</sup>C]CO. *Journal of Labelled*  
14  
15 *Compounds and Radiopharmaceuticals*. John Wiley & Sons, Ltd November 1, 2018, pp 949–  
16  
17 987. <https://doi.org/10.1002/jlcr.3645>.
- 18  
19  
20  
21 (9) Friis, S. D.; Lindhardt, A. T.; Skrydstrup, T. The Development and Application of Two-Chamber  
22  
23 Reactors and Carbon Monoxide Precursors for Safe Carbonylation Reactions. *Acc. Chem. Res.*  
24  
25 **2016**, 49 (4), 594–605. <https://doi.org/10.1021/acs.accounts.5b00471>.
- 26  
27  
28 (10) Zhang, J.; Hou, Y.; Ma, Y.; Szostak, M. Synthesis of Amides by Mild Palladium-Catalyzed  
29  
30 Aminocarbonylation of Arylsilanes with Amines Enabled by Copper(II) Fluoride. *J. Org. Chem.*  
31  
32 **2019**, 84 (1), 338–345. <https://doi.org/10.1021/acs.joc.8b02874>.
- 33  
34  
35 (11) Sumino, S.; Fusano, A.; Fukuyama, T.; Ryu, I. Carbonylation Reactions of Alkyl Iodides through  
36  
37 the Interplay of Carbon Radicals and Pd Catalysts. *Acc. Chem. Res.* **2014**, 47 (5), 1563–1574.  
38  
39 <https://doi.org/10.1021/ar500035q>.
- 40  
41  
42 (12) Chow, S. Y.; Odell, L. R.; Eriksson, J. Low-Pressure Radical C-Aminocarbonylation of Alkyl  
43  
44 Iodides through Thermal Initiation. *European J. Org. Chem.* **2016**, No. 36, 5980–5989.  
45  
46 <https://doi.org/10.1002/ejoc.201601106>.
- 47  
48  
49 (13) Chow, S. Y.; Stevens, M. Y.; Åkerbladh, L.; Bergman, S.; Odell, L. R. Mild and Low-Pressure Fac  
50  
51 -Ir(ppy)<sub>3</sub>-Mediated Radical Aminocarbonylation of Unactivated Alkyl Iodides through Visible-  
52  
53 Light Photoredox Catalysis. *Chem. - A Eur. J.* **2016**, 22 (27), 9155–9161.  
54  
55 <https://doi.org/10.1002/chem.201601694>.
- 56  
57  
58 (14) Roslin, S.; Odell, L. R. Palladium and Visible-Light Mediated Carbonylative Suzuki–Miyaura  
59  
60

- 1  
2  
3 Coupling of Unactivated Alkyl Halides and Aryl Boronic Acids. *Chem. Commun.* **2017**, 53 (51),  
4 6895–6898. <https://doi.org/10.1039/C7CC02763J>.  
5  
6  
7  
8  
9 (15) Collin, H. P.; Reis, W. J.; Nielsen, D. U.; Lindhardt, A. T.; Valle, M. S.; Freitas, R. P.; Skrydstrup,  
10 T. COtab: Expedient and Safe Setup for Pd-Catalyzed Carbonylation Chemistry. *Org. Lett.*  
11 **2019**, 21 (15), 5775–5778. <https://doi.org/10.1021/acs.orglett.9b01423>.  
12  
13  
14  
15 (16) Purwanto; Deshpande, R. M.; Chaudhari, R. V.; Delmas, H. Solubility of Hydrogen, Carbon  
16 Monoxide, and 1-Octene in Various Solvents and Solvent Mixtures. *J. Chem. Eng. Data* **2002**,  
17 *41* (6), 1414–1417. <https://doi.org/10.1021/je960024e>.  
18  
19  
20  
21  
22 (17) Elmore, C. S.; Schenk, D. J.; Arent, R.; Kingston, L. Evaluation of UV-HPLC and Mass  
23 Spectrometry Methods for Specific Activity Determination. *J. Label. Compd. Radiopharm.*  
24 **2014**, 57 (11), 645–651. <https://doi.org/10.1002/jlcr.3234>.  
25  
26  
27  
28  
29 (18) Pauli, G. F.; Chen, S.-N.; Simmler, C.; Lankin, D. C.; Gödecke, T.; Jaki, B. U.; Friesen, J. B.;  
30 McAlpine, J. B.; Napolitano, J. G. Importance of Purity Evaluation and the Potential of  
31 Quantitative <sup>1</sup>H NMR as a Purity Assay. *J. Med. Chem.* **2014**, 57 (22), 9220–9231.  
32 <https://doi.org/10.1021/jm500734a>.  
33  
34  
35  
36  
37  
38  
39 (19) Liu, Y.; Sun, H.; Huang, Z.; Ma, C.; Lin, A.; Yao, H.; Xu, J.; Xu, S. Metal-Free Synthesis of N -  
40 (Pyridine-2-yl)amides from Ketones via Selective Oxidative Cleavage of C(O)–C(Alkyl) Bond in  
41 Water. *J. Org. Chem.* **2018**, 83 (23), 14307–14313. <https://doi.org/10.1021/acs.joc.8b01956>.  
42  
43  
44  
45  
46  
47 (20) Ghosh, S. C.; Ngiam, J. S. Y.; Seayad, A. M.; Tuan, D. T.; Chai, C. L. L.; Chen, A. Copper-  
48 Catalyzed Oxidative Amidation of Aldehydes with Amine Salts: Synthesis of Primary,  
49 Secondary, and Tertiary Amides. *J. Org. Chem.* **2012**, 77 (18), 8007–8015.  
50 <https://doi.org/10.1021/jo301252c>.  
51  
52  
53  
54  
55  
56 (21) Sugimoto, M.; Yamamoto, F.; Honna, K.; Kurisaki, K.; Sugahara, H.; Watanabe, K.; Fujimoto, Y.;  
57 Ryu, S. Adamantane-Piperazine Derivatives. US4001223, 1975.  
58  
59  
60

- 1  
2  
3 (22) Dhanasekaran, S.; Suneja, A.; Bisai, V.; Singh, V. K. Approach to Isoindolinones,  
4 Isoquinolinones, and THIQs via Lewis Acid-Catalyzed Domino Strecker-  
5 Lactamization/Alkylations. *Org. Lett.* **2016**, *18* (4), 634–637.  
6  
7  
8  
9  
10 <https://doi.org/10.1021/acs.orglett.5b03331>.  
11  
12  
13 (23) Neumann, K. T.; Donslund, A. S.; Andersen, T. L.; Nielsen, D. U.; Skrydstrup, T. Synthesis of  
14 Aliphatic Carboxamides Mediated by Nickel NN2-Pincer Complexes and Adaptation to  
15 Carbon-Isotope Labeling. *Chem. - A Eur. J.* **2018**, *24* (56), 14946–14949.  
16  
17  
18  
19 <https://doi.org/10.1002/chem.201804077>.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60